Interleukin-17 receptor antagonist reduces inflammatory response in experimental periodontitis
Aim or Purpose: Interleukin (IL)-17 is one of the inflammatory cytokines caused periodontitis and psoriasis. Psoriasis, a chronic inflammatory skin disease, treats with IL-17 receptor antagonist (brodalumab: BRD). However, little is known about the effect of BRD on periodontitis. This study was eval...
Saved in:
Main Authors: | Dr Takenori Sato (Author), Dr. Keisuke Handa (Author) |
---|---|
Format: | Book |
Published: |
Elsevier,
2023-09-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Mitoprotective effect of the receptor antagonist interleukin-1 in experimental cerebral stroke
by: E. V. Suprun
Published: (2012) -
Interleukin-7 receptor blockade suppresses adaptive and innate inflammatory responses in experimental colitis
by: Willis Cynthia R, et al.
Published: (2012) -
The interleukin-1 receptor antagonist influences interleukin-1 effects in rat and mouse
by: P. Bjrök, et al.
Published: (1992) -
Serum interleukin-17 (IL-17) in chronic periodontitis patients
by: Erry Mochamad Arief, et al.
Published: (2017) -
Woronoff Ring in Deficiency of Interleukin-36 Receptor Antagonist (DITRA)
by: Daniel Morgado-Carasco, et al.
Published: (2019)